Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients

J Heart Lung Transplant. 2005 Sep;24(9):1440-3. doi: 10.1016/j.healun.2004.08.006.

Abstract

Short-term improvement in lung function was observed in 5 of 6 lung transplant recipients with bronchiolitis obliterans syndrome (BOS) who were treated with oral azithromycin. We assessed the long-term effect (mean duration 10 months) of treatment with oral azithromycin in 11 lung transplant recipients with BOS. Mean forced expiratory volume in 1 second (FEV1) was 40 +/- 9% at initiation of azithromycin treatment, 39 +/- 10% after 1 month, 39 +/- 12% after 4 months, 38 +/- 10% after 7 months and 38 +/- 10% after 10 months, respectively (statistically non-significant for all data). We conclude that long-term administration with oral azithromycin does not reverse BOS in lung transplant recipients, but may slow progression of the disease.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / pharmacology
  • Azithromycin / therapeutic use*
  • Bronchiolitis Obliterans / drug therapy*
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume / drug effects
  • Humans
  • Lung / drug effects
  • Lung / physiology
  • Lung Transplantation*
  • Male
  • Middle Aged
  • Pilot Projects
  • Postoperative Complications / drug therapy*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Azithromycin